Clinical trials
Terminated Phase 1/2 Carcinoma, Non-Small-Cell Lung trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
129 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 3 |
| 2006 | 3 |
| 2007 | 7 |
| 2008 | 6 |
| 2009 | 4 |
| 2010 | 5 |
| 2012 | 3 |
| 2014 | 2 |
| 2015 | 15 |
| 2016 | 6 |
| 2017 | 15 |
| 2018 | 10 |
| 2019 | 4 |
| 2020 | 9 |
| 2021 | 10 |
| 2022 | 12 |
| 2023 | 8 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 129 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 6 |
| Incyte Corporation | 4 |
| Clovis Oncology, Inc. | 3 |
| Genmab | 3 |
| National Cancer Institute (NCI) | 3 |
| Bristol-Myers Squibb | 2 |
| Dana-Farber Cancer Institute | 2 |
| Fred Hutchinson Cancer Center | 2 |
| GlaxoSmithKline | 2 |
| H. Lee Moffitt Cancer Center and Research Institute | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 129 |
| Lung Neoplasms | 30 |
| Melanoma | 18 |
| Colorectal Neoplasms | 17 |
| Triple Negative Breast Neoplasms | 17 |
| Neoplasm Metastasis | 16 |
| Squamous Cell Carcinoma of Head and Neck | 16 |
| Ovarian Neoplasms | 12 |
| Breast Neoplasms | 11 |
| Neoplasms | 11 |
Trials
Showing 1 to 25 of 129. Each trial links to its page on Pharma Observatory.
29 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.